Rob Faulkner
Managing Director
Works at Redmile Group
Investor profile | Builders Republic
About
Managing Director at Redmile Group in San Francisco, Rob Faulkner invests from Series A to Pre-IPO as well as in publicly traded companies, with a specialized health thesis covering medtech, digital health, and biotech. His portfolio includes notable companies such as Science 37 (digital clinical trials), Saluda Medical (neuromodulation), and Impulse Dynamics (cardiac devices). He chaired the board of Science 37 until its acquisition in 2024. Prior to Redmile, he spent 6 years as Managing Director at JPMorgan (Hambrecht & Quist), and held similar roles at Prudential, JMP Securities, and Thomas Weisel Partners. He graduated from Harvard University.
Profile
- Role
- Managing Director
- Fund
- Redmile Group
- Nationality
- American